-+ 0.00%
-+ 0.00%
-+ 0.00%

Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension

Barchart·10/05/2026 10:45:00
Listen to the news

Two oral presentations at AHA Hypertension 2026 will highlight the substantial antihypertensive efficacy of aprocitentan in two hypertension populations from the PRECISION study: patients with obesity and patients across the cardiovascular-kidney-metabolic (CKM) continuum.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.